Adamis Pharmaceuticals Corp represents a strong dedication to delivering innovative and high-quality healthcare solutions. The company's core values revolve around putting patients first and striving for excellence in all areas of operation. Adamis Pharmaceuticals Corp is committed to providing accessible and affordable medications to improve the lives of individuals worldwide. With a focus on constantly developing and advancing pharmaceutical products, the company aims to make a positive impact on the healthcare industry. By prioritizing innovation, quality, and patient-centered care, Adamis Pharmaceuticals Corp strives to establish itself as a trusted and reliable partner in the pharmaceutical market.

Adamis Pharmaceuticals Corp is primarily present in the United States.

Adamis Pharmaceuticals Corp has achieved several significant milestones. One notable accomplishment is the FDA approval of their flagship product, Symjepi, which is an epinephrine injection for the emergency treatment of allergic reactions. Additionally, the company has successfully launched other pharmaceutical products in the market, such as ZIMHI for opioid overdose and Tempol for COVID-19 treatment. Adamis Pharmaceuticals Corp has also established strategic partnerships and collaborations to expand their product pipeline and improve patient care. These achievements demonstrate the company's commitment to innovation and their dedication to addressing critical medical needs.

Adamis Pharmaceuticals Corp is a pharmaceutical company specializing in the development and commercialization of therapeutic products. Established in 2006, the company primarily focuses on developing treatments for respiratory disease, allergies, and opioid overdose. Adamis Pharmaceuticals Corp is recognized for its innovation and dedication in providing effective healthcare solutions to patients. With a strong portfolio of products and ongoing research and development efforts, the company strives to improve the lives of individuals worldwide. Adamis Pharmaceuticals Corp continues to uphold its commitment to delivering high-quality pharmaceuticals and is a prominent player in the healthcare industry.

Adamis Pharmaceuticals Corp faces competition from several companies in the market. Some of its main competitors include Teva Pharmaceutical Industries Ltd., Mylan N.V., and GlaxoSmithKline plc. These companies also operate in the pharmaceutical industry, offering similar products and services. It is essential for Adamis Pharmaceuticals Corp to stay competitive by constantly innovating, developing new drugs, and maintaining high product quality. By closely monitoring its competitors and adapting its strategies accordingly, Adamis Pharmaceuticals Corp can strive to achieve a dominant position in the market and continue delivering value to its customers and stakeholders.

Adamis Pharmaceuticals Corp is primarily active in the healthcare and pharmaceutical industries.

Adamis Pharmaceuticals Corp is a company with a business model focused on the development and commercialization of specialty pharmaceutical products. They aim to provide innovative and cost-effective treatment options for various medical conditions, including respiratory disease, allergy, and opioid overdose. Adamis Pharmaceuticals Corp seeks to leverage their expertise in drug delivery systems to develop and improve existing medications. With a commitment to meeting unmet medical needs, they strive to enhance patient outcomes and provide value to healthcare professionals and consumers alike.

Adamis Pharmaceuticals KGV ir 0,18.

Adamis Pharmaceuticals KUV ir 0,03.

AlleAktien kvalitātes vērtējums Adamis Pharmaceuticals ir 6/10.

gaidāmā Adamis Pharmaceuticals apgrozījums ir 35,07 milj. USD.

gaidāmā Adamis Pharmaceuticals peļņa ir 6,12 milj. USD.

Adamis Pharmaceuticals Corp is a US pharmaceutical company specializing in the development and marketing of innovative medications and biological therapies. The company operates in several divisions, including allergy and immunology products, pulmonology products, oncology products, and veterinary products. The company's business model includes partnerships and licensing agreements with other biopharmaceutical companies, as well as targeted marketing strategies and the use of modern technologies and digital tools to promote their products and services. The goal of the company is to expand its position in the biopharmaceutical market through strong partnerships and a targeted marketing strategy.

Adamis Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Adamis Pharmaceuticals vai uzņēmums nedod dividendes.

Adamis Pharmaceuticals ISIN ir US00547W2089.

Adamis Pharmaceuticals WKN ir A1XA2F.

Adamis Pharmaceuticals simbols ir ADMP.

Pēdējo 12 mēnešu laikā Adamis Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Adamis Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Adamis Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Adamis Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Adamis Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Adamis Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Adamis Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 10.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 10.10.2024..

Pēdējās dividendes izmaksa notika 10.10.2024..

Gadā 2023, Adamis Pharmaceuticals izmaksāja 0 USD dividendes.

Adamis Pharmaceuticals dividendes tiek izmaksātas USD.